Myriad Genetics (MYGN) Competitors

Myriad Genetics logo
$5.57 -0.09 (-1.59%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$5.64 +0.06 (+1.17%)
As of 05:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MYGN vs. REPL, IMNM, VCYT, RXRX, and COAG

Should you buy Myriad Genetics stock or one of its competitors? Myriad Genetics's main competitors and comparable companies include Replimune Group (REPL), Immunome (IMNM), Veracyte (VCYT), Recursion Pharmaceuticals (RXRX), and Hemab Therapeutics (COAG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Myriad Genetics compare to Replimune Group?

Myriad Genetics (NASDAQ:MYGN) and Replimune Group (NASDAQ:REPL) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Myriad Genetics currently has a consensus price target of $5.98, suggesting a potential upside of 7.34%. Replimune Group has a consensus price target of $18.17, suggesting a potential downside of 15.15%. Given Myriad Genetics' higher possible upside, research analysts clearly believe Myriad Genetics is more favorable than Replimune Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myriad Genetics
1 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Replimune Group
2 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Replimune Group had 2 more articles in the media than Myriad Genetics. MarketBeat recorded 9 mentions for Replimune Group and 7 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.85 beat Replimune Group's score of 0.50 indicating that Myriad Genetics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Myriad Genetics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Replimune Group
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Replimune Group has lower revenue, but higher earnings than Myriad Genetics. Replimune Group is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myriad Genetics$824.50M0.65-$365.90M-$1.36N/A
Replimune GroupN/AN/A-$313.94M-$2.79N/A

Myriad Genetics has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

Replimune Group has a net margin of 0.00% compared to Myriad Genetics' net margin of -16.07%. Myriad Genetics' return on equity of -19.87% beat Replimune Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Myriad Genetics-16.07% -19.87% -9.67%
Replimune Group N/A -157.78%-83.89%

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by insiders. Comparatively, 5.4% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Myriad Genetics beats Replimune Group on 8 of the 14 factors compared between the two stocks.

How does Myriad Genetics compare to Immunome?

Myriad Genetics (NASDAQ:MYGN) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Immunome has a net margin of 0.00% compared to Myriad Genetics' net margin of -16.07%. Myriad Genetics' return on equity of -19.87% beat Immunome's return on equity.

Company Net Margins Return on Equity Return on Assets
Myriad Genetics-16.07% -19.87% -9.67%
Immunome N/A -51.33%-47.63%

Myriad Genetics has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, Immunome has a beta of 2.68, meaning that its share price is 168% more volatile than the broader market.

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by insiders. Comparatively, 7.2% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Immunome has lower revenue, but higher earnings than Myriad Genetics. Immunome is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myriad Genetics$824.50M0.65-$365.90M-$1.36N/A
Immunome$6.94M299.60-$212.39M-$2.64N/A

Myriad Genetics presently has a consensus target price of $5.98, indicating a potential upside of 7.34%. Immunome has a consensus target price of $33.85, indicating a potential upside of 92.20%. Given Immunome's stronger consensus rating and higher probable upside, analysts clearly believe Immunome is more favorable than Myriad Genetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myriad Genetics
1 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Immunome
1 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.81

In the previous week, Immunome had 16 more articles in the media than Myriad Genetics. MarketBeat recorded 23 mentions for Immunome and 7 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.85 beat Immunome's score of -0.05 indicating that Myriad Genetics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Myriad Genetics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Immunome
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Immunome beats Myriad Genetics on 9 of the 16 factors compared between the two stocks.

How does Myriad Genetics compare to Veracyte?

Myriad Genetics (NASDAQ:MYGN) and Veracyte (NASDAQ:VCYT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Veracyte has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myriad Genetics$824.50M0.65-$365.90M-$1.36N/A
Veracyte$517.15M3.75$66.35M$1.5515.49

In the previous week, Veracyte had 9 more articles in the media than Myriad Genetics. MarketBeat recorded 16 mentions for Veracyte and 7 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.85 beat Veracyte's score of 0.03 indicating that Myriad Genetics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Myriad Genetics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Veracyte
3 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral

99.0% of Myriad Genetics shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by insiders. Comparatively, 1.6% of Veracyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Myriad Genetics presently has a consensus target price of $5.98, indicating a potential upside of 7.34%. Veracyte has a consensus target price of $44.50, indicating a potential upside of 85.34%. Given Veracyte's stronger consensus rating and higher possible upside, analysts plainly believe Veracyte is more favorable than Myriad Genetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myriad Genetics
1 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Veracyte
1 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.42

Myriad Genetics has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market. Comparatively, Veracyte has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market.

Veracyte has a net margin of 21.80% compared to Myriad Genetics' net margin of -16.07%. Veracyte's return on equity of 8.99% beat Myriad Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Myriad Genetics-16.07% -19.87% -9.67%
Veracyte 21.80%8.99%8.34%

Summary

Veracyte beats Myriad Genetics on 12 of the 16 factors compared between the two stocks.

How does Myriad Genetics compare to Recursion Pharmaceuticals?

Myriad Genetics (NASDAQ:MYGN) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Myriad Genetics has a net margin of -16.07% compared to Recursion Pharmaceuticals' net margin of -697.15%. Myriad Genetics' return on equity of -19.87% beat Recursion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Myriad Genetics-16.07% -19.87% -9.67%
Recursion Pharmaceuticals -697.15%-47.85%-36.26%

In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than Myriad Genetics. MarketBeat recorded 10 mentions for Recursion Pharmaceuticals and 7 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.85 beat Recursion Pharmaceuticals' score of 0.13 indicating that Myriad Genetics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Myriad Genetics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Recursion Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 1.9% of Myriad Genetics shares are held by company insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Myriad Genetics has higher revenue and earnings than Recursion Pharmaceuticals. Myriad Genetics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myriad Genetics$824.50M0.65-$365.90M-$1.36N/A
Recursion Pharmaceuticals$74.68M24.18-$644.76M-$0.90N/A

Myriad Genetics currently has a consensus target price of $5.98, indicating a potential upside of 7.34%. Recursion Pharmaceuticals has a consensus target price of $7.58, indicating a potential upside of 161.38%. Given Recursion Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Myriad Genetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myriad Genetics
1 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Recursion Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

Myriad Genetics has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Summary

Myriad Genetics and Recursion Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Myriad Genetics compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Myriad Genetics (NASDAQ:MYGN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

In the previous week, Hemab Therapeutics had 2 more articles in the media than Myriad Genetics. MarketBeat recorded 9 mentions for Hemab Therapeutics and 7 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.85 beat Hemab Therapeutics' score of 0.05 indicating that Myriad Genetics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hemab Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Myriad Genetics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Hemab Therapeutics has higher earnings, but lower revenue than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemab TherapeuticsN/AN/AN/A-$24.78N/A
Myriad Genetics$824.50M0.65-$365.90M-$1.36N/A

Hemab Therapeutics has a net margin of 0.00% compared to Myriad Genetics' net margin of -16.07%. Hemab Therapeutics' return on equity of 0.00% beat Myriad Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemab TherapeuticsN/A N/A N/A
Myriad Genetics -16.07%-19.87%-9.67%

Hemab Therapeutics currently has a consensus price target of $56.00, indicating a potential upside of 43.37%. Myriad Genetics has a consensus price target of $5.98, indicating a potential upside of 7.34%. Given Hemab Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Hemab Therapeutics is more favorable than Myriad Genetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hemab Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70
Myriad Genetics
1 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

99.0% of Myriad Genetics shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Hemab Therapeutics beats Myriad Genetics on 7 of the 12 factors compared between the two stocks.

Get Myriad Genetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MYGN vs. The Competition

MetricMyriad GeneticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$544.84M$4.15B$7.84B$12.17B
Dividend YieldN/A3.62%2.46%4.43%
P/E Ratio-4.1027.6734.7128.60
Price / Sales0.6516.368.635.70
Price / Cash1.5126.3721.9322.50
Price / Book1.994.074.323.70
Net Income-$365.90M-$22.86M$3.52B$392.17M
7 Day Performance-1.76%-6.13%-4.44%-3.21%
1 Month Performance39.95%-4.90%-3.49%-5.66%
1 Year Performance-16.37%-2.99%0.19%-5.97%

Myriad Genetics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MYGN
Myriad Genetics
2.3436 of 5 stars
$5.57
-1.6%
$5.98
+7.3%
-17.0%$544.84M$824.50MN/A2,700
REPL
Replimune Group
1.5351 of 5 stars
$22.67
+1.8%
$14.33
-36.8%
+138.2%$2.12BN/AN/A465
IMNM
Immunome
2.48 of 5 stars
$18.73
-3.3%
$33.85
+80.7%
+2.7%$2.11B$6.94MN/A177
VCYT
Veracyte
3.2435 of 5 stars
$25.48
-1.7%
$46.00
+80.6%
-39.0%$2.03B$517.15M16.29755
RXRX
Recursion Pharmaceuticals
2.9865 of 5 stars
$3.66
-4.1%
$8.18
+123.8%
-30.0%$1.96B$74.68MN/A600

Related Companies and Tools


This page (NASDAQ:MYGN) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners